Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Search Seller Projects – ,

Page of 19
Asia: Hong Kong SAR

Hong Kong owned Chengdu clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications include internal medicine, pediatrics, gynecology, surgery, women's health care, children's health care, ophthalmology, otorhinolaryngology, stomatology, dermatology, traditional Chinese medicine inspection, and imaging (ultrasound). The company has a comprehensive medical licence and the speciality qualification and decoration setting of dermatology, stomatology and women's and children's health care. It is Hong Kong-listed. Its medical licence is valid from May 26, 2020 to May 25, 2025. The company seeks the sale of the clinic in Chengdu or cooperation.
Asia: Hong Kong SAR

Hong Kong owned Beijing clinic seeks new owner or cooperation.

The Hong Kong company's scope of medical qualifications includes internal medicine, surgery, gynecology and obstetrics (gynecology), pediatrics, ophthalmology, otorhinolaryngology, stomatology, dermatology, psychiatry, traditional Chinese medicine inspection, and imaging (X-ray, ultrasound, electrocardiogram ("ECG")). In the Chaoyang district of Beijing, the comprehensive outpatient department licence is scarce. The company is Hong Kong-listed. It seeks the sale of the clinic in Beijing or cooperation.
Asia: Israel

Israeli sales analytics company seeks USD 3 million financing.

Through professional data analysis, the Israeli company's Software as a Service ("SaaS") platform helps distribution companies improve sales and profits. The company's product has insightful proprietary algorithms that analyze the company's sales and marketing data and external data sets to provide sales and marketing agents with specific recommended action "insights" on how to increase revenue and where to realize unrealized business opportunities. Existing data show that one month's use has brought 14% additional revenue to customers. The company seeks USD 3 million financing.
Asia: South Korea

Korean Alzheimer's diagnosis technology company seeks investment.

The Korean company's Alzheimer's diagnosis technology has the original myelodysplastic syndromes ("MDS") technology (polymer detection technology), which is an original technology for early diagnosis of protein conformational diseases. The company has developed products for early and accurate diagnosis of Alzheimer's disease through blood samples. The company's original MDS technology can be used as a platform technology for diagnosis of all protein conformational diseases. Compared with current technology, the company's Blood Amyloid-β Oligomerization detection technology has the advantages of small amount of blood collection, simple method, quantitative detection, no need for expensive analytical instruments, early diagnosis and so on. In the future, based on MDS platform technology, the company's technology can also be used to detect Parkinson's disease. The company now seeks investment.
Asia: South Korea

Korean biopharma company seeks investment.

The Korean company began to expand its products since 2011, when it obtained the product licence of hyaluronic acid ("HA") injections. It has obtained the patent for manufacturing equipment and method of HA inducible factor. The company's anti-adhesion materials have obtained Good Manufacturing Practice ("GMP") certification and the collagen repair patch has obatined the medical device certification. The company has completed the botulinum toxin clinical phase I and II (phase III investigational new drug ("IND") application) trials, which were listed in the Korean Securities Dealers Automated Quotations ("KOSDAQ"). At present, the company's medical device factory in Daegu is a special factory for biomedical instruments, which can produce mesotherapy products such as HA/DNA injections, wound repair and tissue supplement materials, etc. in a modular manner. In the future, an Sejong GMP factory will be added for mass production of specialized medicines, bulk medicines, botulinum toxin, peptide for treating brain diseases, antiviral medicines for liver diseases, etc. In 2019, the company's export reached USD 6.24 million (KRW 7.8 billion) with 40 export countries. The company now seeks investment.
Asia: South Korea

Korean clothing retail company seeks to issue new shares.

The company operates the business of five well-known Korean clothing brands in China, including men's and women's clothing. Its sales channels include 1331 nationwide stores (covering the first to third tier cities) and T-mall flagship stores of 5 brands. The company is headquartered in Shanghai. Its parent company is a Korean-listed company. The company seeks to issue new shares to offer its controlling interest and management rights.
Asia: Japan

Japanese cosmetics company seeks 100% equity transfer priced at USD 4.74 million.

The Hokkaido's company is mainly engaged in the research and development and sales of its own brand cosmetics and skin care products. Additionally, the company provides original equipment manufacturer ("OEM") services for the other enterprises. All its products are made of natural materials in Japan. The company seeks 100% equity transfer priced at USD 4.74 million (JPY 600 million).
Asia: Japan

Japanese old brand winery company seeks 100% equity transfer priced at USD 3 million.

The Nagoya company is mainly engaged in the production and sales of Japanese wine and shochu. The company's annual sales are USD 4.424 million (JPY 560 million). It has made exports to more than 10 countries. The company seeks 100% equity transfer priced at USD 3 million (JPY 380 million).
Asia: South Korea

Korean biotechnology company seeks USD 5 million equity financing.

The Korean company has developed the bioelectronic nose sensor technology based on human olfactory receptor and uses it to manufacture medical devices for early cancer diagnosis. The company's bioelectronic nose sensor is a super sensitive sensor, which can detect cancer earlier than any sensor or instrument. The examinee only needs to exhale on the inspection machine for about 1 minute to complete the inspection. There is no discomfort during the inspection. In addition, due to the mass production technology of sensors, the manufacturing cost of sensors is low and so the inspection cost is very low. The company has completed the development of a special bioelectronic nose sensor for early diagnosis of gastric cancer in 2019 and has completed three olfactory receptor sensors, all of which have been registered for patent. The expiratory examination instrument products will be licenced for sale through clinical trials in a short period. The company seeks USD 5 million for equity financing.
Asia: South Korea

Korean vital sign monitoring R&D company seeks USD 8.4 million equity financing.

The Korean company has the original technology of extracting heart information (heart rate, pressure and heart rate variability) through human pupil, and provides the above original technology and daily health management scheme for various terminals such as smart phones. Compared with wearable devices, the company's products have strong convenience. Its products can be switched on and integrated into the daily operation of smart phones without skin induction, and use the front camera to tract the rhythm of pupil dilation. Additionally, the company's products are widely used in many fields. The main application fields are psychological counseling services, telemedicine enterprises, communication companies and equipment manufacturers. The company seeks USD 8.4 million for equity financing.
Asia: South Korea

Korean logistics automation development company seeks USD 3-6 million equity financing.

The Korean company provides intelligent factories with logistics automation systems including storage, packaging and transfer, but also effective solutions for the whole process of online order response. In addition, the company provides intelligent solutions and services for logistics enterprises. The core team has rich technical operation and system development capabilities, which has successfully sold their services to NXP (Thailand) at USD 368K (KRW 460 million). The company seeks USD 3-6 million for equity financing.
Asia: Singapore

Singaporean ophthalmic disease treatment company seeks investment.

The Singaporean company focuses on the treatment of ophthalmic diseases, including corneal transplantation, retinal surgery, myopia control and so on. There are 6 local professional treatment centers and 11 senior ophthalmologists. As of May 2021, the net profit after salaries is approximately USD 7.28 million (SGD 10 million). Now the company seeks investment.

Filter

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive